Table 3.

Reasons for discontinuation of 5GPE-SLIT before the end-of-study follow-up visit

	Children (N = 203)	Adults (N = 280)	Total (N = 483)
Discontinuation before the start of the pollen season	N = 18	N = 34	N = 52
Planned end of treatment course	1 (5.6%)	2 (5.9%)	3 (5.8%)
Patient decision	2 (11.1%)	3 (8.8%)	5 (9.6%)
Occurrence of an adverse event	14 (77.8%)	27 (79.4%)	41 (78.8%)
Other	1 (5.6%)	2 (5.9%)	3 (5.8%)
Discontinuation after the start of the pollen season	N = 150	N = 191	N = 341
Planned end of treatment course	136 (90.7%)	172 (90.1%)	308 (90.3%)
Patient decision	5 (3.3%)	8 (4.2%)	13 (3.8%)
Lack of efficacy	1 (0.7%)	1 (0.5%)	2 (0.6%)
Occurrence of an adverse event	None	2 (1.0%)	2 (0.6%)
Other	3 (2.0%)	1 (0.5%)	4 (1.2%)
Not documented	5 (3.3%)	7 (3.7%)	12 (3.5%)

Reasons for discontinuation are not mutually exclusive and more than one reason can this be documented in any given patient